<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
<journal-id journal-id-type="pmc">ploscomp</journal-id><journal-title-group>
<journal-title>PLoS Computational Biology</journal-title></journal-title-group>
<issn pub-type="ppub">1553-734X</issn>
<issn pub-type="epub">1553-7358</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PCOMPBIOL-D-13-01379</article-id>
<article-id pub-id-type="doi">10.1371/journal.pcbi.1003878</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology and life sciences</subject><subj-group><subject>Computational biology</subject><subj-group><subject>Population modeling</subject><subj-group><subject>Infectious disease modeling</subject></subj-group></subj-group><subj-group><subject>Evolutionary modeling</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>The Route of HIV Escape from Immune Response Targeting Multiple Sites Is Determined by the Cost-Benefit Tradeoff of Escape Mutations</article-title>
<alt-title alt-title-type="running-head">The Route of HIV Escape from Immune Response</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Batorsky</surname><given-names>Rebecca</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sergeev</surname><given-names>Rinat A.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="fn" rid="fn1"><sup>¤a</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Rouzine</surname><given-names>Igor M.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref><xref ref-type="fn" rid="fn2"><sup>¤b</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>Department of Physics and Astronomy, Tufts University, Medford, Massachusetts, United States of America</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, United States of America</addr-line></aff>
<aff id="aff3"><label>3</label><addr-line>Department of Microbiology, Tufts University, Boston, Massachusetts, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Althaus</surname><given-names>Christian L.</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Bern, Switzerland</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">igor.rouzine@gladstone.ucsf.edu</email></corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
<fn fn-type="con"><p>Conceived and designed the experiments: RB RAS IMR. Performed the experiments: RB. Analyzed the data: RB. Contributed reagents/materials/analysis tools: RB RAS IMR. Wrote the paper: RB IMR.</p></fn>
<fn id="fn1" fn-type="current-aff"><label>¤a</label><p>Current address: Institute for Quantitative Social Science, Harvard University, Cambridge, Massachusetts, United States of America</p></fn>
<fn id="fn2" fn-type="current-aff"><label>¤b</label><p>Current address: Gladstone Institute of Virology and Immunology, University of California, San Francisco, San Francisco, California, United States of America</p></fn>
</author-notes>
<pub-date pub-type="collection"><month>10</month><year>2014</year></pub-date>
<pub-date pub-type="epub"><day>30</day><month>10</month><year>2014</year></pub-date>
<volume>10</volume>
<issue>10</issue>
<elocation-id>e1003878</elocation-id>
<history>
<date date-type="received"><day>3</day><month>8</month><year>2013</year></date>
<date date-type="accepted"><day>21</day><month>8</month><year>2014</year></date>
</history>
<permissions>
<copyright-year>2014</copyright-year>
<copyright-holder>Batorsky et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract>
<p>Cytotoxic T lymphocytes (CTL) are a major factor in the control of HIV replication. CTL arise in acute infection, causing escape mutations to spread rapidly through the population of infected cells. As a result, the virus develops partial resistance to the immune response. The factors controlling the order of mutating epitope sites are currently unknown and would provide a valuable tool for predicting conserved epitopes. In this work, we adapt a well-established mathematical model of HIV evolution under dynamical selection pressure from multiple CTL clones to include partial impairment of CTL recognition, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e001" xlink:type="simple"/></inline-formula>, as well as cost to viral replication, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e002" xlink:type="simple"/></inline-formula>. The process of escape is described in terms of the cost-benefit tradeoff of escape mutations and predicts a trajectory in the cost-benefit plane connecting sequentially escaped sites, which moves from high recognition loss/low fitness cost to low recognition loss/high fitness cost and has a larger slope for early escapes than for late escapes. The slope of the trajectory offers an interpretation of positive correlation between fitness costs and HLA binding impairment to HLA-A molecules and a protective subset of HLA-B molecules that was observed for clinically relevant escape mutations in the Pol gene. We estimate the value of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e003" xlink:type="simple"/></inline-formula> from published experimental studies to be in the range (0.01–0.86) and show that the assumption of complete recognition loss (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e004" xlink:type="simple"/></inline-formula>) leads to an overestimate of mutation cost. Our analysis offers a consistent interpretation of the commonly observed pattern of escape, in which several escape mutations are observed transiently in an epitope. This non-nested pattern is a combined effect of temporal changes in selection pressure and partial recognition loss. We conclude that partial recognition loss is as important as fitness loss for predicting the order of escapes and, ultimately, for predicting conserved epitopes that can be targeted by vaccines.</p>
</abstract>
<abstract abstract-type="summary"><title>Author Summary</title>
<p>Like many viruses, HIV has evolved mechanisms to evade the host immune response. As early as a few weeks after infection is initiated, mutations appear in the viral genome that reduce the ability of cytotoxic T lymphocytes (CTL) to control virus replication. However, of the many mutations in the viral genome that could potentially mediate viral escape from the CTL response, a specific subset are typically observed. This suggests that some mutations either entail too high a fitness cost for the virus, or are relatively inefficient escape mutations. A successful vaccine would target the CTL response to these regions in such a way that escape would not be possible. We use a computational model of HIV infection in order to study the factors that determine whether a given escape mutation will occur, how long it will be maintained in the population, and how these changes in the viral genome will affect the CTL response. Our analysis highlights the important role of partial recognition loss conferred by a mutation in producing the complex dynamics of escape that are observed during the course of infection.</p>
</abstract>
<funding-group><funding-statement>This work was funded by NIH grants R01AI 063926 to IMR and R37CA 089441 to John Coffin. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="12"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>HIV replication continues for years despite a highly active immune response. Depletion of cytotoxic CD8+ T cells (CTL) in SIV infected animals causes rapid increase in viremia <xref ref-type="bibr" rid="pcbi.1003878-Schmitz1">[1]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Jin1">[2]</xref> showing that CTL control HIV/SIV replication; that this response is antigen-specific is evident from rapid genetic evolution of HIV in antigenically important regions. Antigenic escape is one of the major mechanisms of HIV resilience in face of an active immune response, impeding effective vaccine design <xref ref-type="bibr" rid="pcbi.1003878-Finlay1">[3]</xref> and implicated in the progression to AIDS <xref ref-type="bibr" rid="pcbi.1003878-Rouzine1">[4]</xref>. Shortly after infection is initiated, many CTL clones arise to target the transmitted virus strain <xref ref-type="bibr" rid="pcbi.1003878-Turnbull1">[5]</xref>–<xref ref-type="bibr" rid="pcbi.1003878-Liu1">[7]</xref>, each clone recognizing a distinct 8–10 amino acid viral peptide (epitope) presented on the surface of an infected cell by MHC molecules. Escape mutations in CTL epitopes begin to be selected within a month of infection and continue to be selected throughout chronic infection, sometimes causing a decrease in the intrinsic replication rate of the virus (fitness cost) <xref ref-type="bibr" rid="pcbi.1003878-Leslie1">[8]</xref>–<xref ref-type="bibr" rid="pcbi.1003878-Troyer1">[10]</xref>. However, despite a sustained CTL response, not all targeted epitopes escape. Moreover, among epitopes that do escape, the rate of escape slows dramatically over the first 100 days post infection. It remains unclear which parameters decide the timing and rate of escape in a given epitope as well as which epitopes escape and which are preserved throughout chronic infection <xref ref-type="bibr" rid="pcbi.1003878-Liu2">[11]</xref>–<xref ref-type="bibr" rid="pcbi.1003878-Henn1">[13]</xref>.</p>
<p>Mathematical models of HIV evolution in the presence of multiple CTL clones have been applied to study the emergence of late escape mutations <xref ref-type="bibr" rid="pcbi.1003878-Althaus1">[14]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Mostowy1">[15]</xref> and the effect of distributed CTL pressure on the rate of escape <xref ref-type="bibr" rid="pcbi.1003878-Ganusov1">[12]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-vanDeutekom1">[16]</xref>. Previous work has emphasized two parameters, the mutation cost (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e005" xlink:type="simple"/></inline-formula>) and the number of active epitopes (<italic>n</italic>). It can be inferred that escape mutations come at a cost from the observation of occasional reversion of escape mutations upon transmission between MHC mismatched individuals <xref ref-type="bibr" rid="pcbi.1003878-Leslie1">[8]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Friedrich1">[9]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Kearney1">[17]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Fryer1">[18]</xref>, as well as the frequent acquisition of compensatory mutations outside escaping epitopes. <xref ref-type="bibr" rid="pcbi.1003878-Kelleher1">[19]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Crawford1">[20]</xref>. Common escape mutations have been shown experimentally to have wide ranging fitness costs <xref ref-type="bibr" rid="pcbi.1003878-Troyer1">[10]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Song1">[21]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Boutwell1">[22]</xref>. However, fitness costs and the number of CTL clones acting on the virus are not the sole determinants of the dynamics of escape. The degree of escape conferred by a mutation is equally important. It has been observed in HIV infected individuals <xref ref-type="bibr" rid="pcbi.1003878-Liu3">[23]</xref> and SIV infected animals <xref ref-type="bibr" rid="pcbi.1003878-Cale1">[24]</xref> that CTL are capable of recognizing different variants of an epitope with different efficiencies. Thus, in general, an escape mutant does not fully abrogate recognition of the corresponding CTL clone.</p>
<p>In the present work, we address the process of antigenic escape in terms of a cost-benefit diagram. The benefit of an escape mutation is a partial CTL recognition loss and the mutation cost is a partial reduction in viral replication rate. We extend the basic model introduced by Althaus and De Boer <xref ref-type="bibr" rid="pcbi.1003878-Althaus1">[14]</xref> to include partially effective escape mutations and investigate how the two opposing evolutionary forces together determine the observed rate of escape from the CTL response <xref ref-type="bibr" rid="pcbi.1003878-Ganusov1">[12]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Ganusov2">[25]</xref>. The model predicts that a positive correlation between recognition and fitness losses emerges during sequential escape mutations, the strength of which changes over time as pressure from the immune system wanes. We compare our model predictions with existing data showing a correlation between fitness and recognition losses in clinically relevant escape mutations from the Pol gene <xref ref-type="bibr" rid="pcbi.1003878-Mostowy2">[26]</xref> and estimate the range of recognition losses that occurs in commonly observed escape mutations from three published studies <xref ref-type="bibr" rid="pcbi.1003878-Schneidewind1">[27]</xref>–<xref ref-type="bibr" rid="pcbi.1003878-Matthews1">[29]</xref>.</p>
<p>Furthermore, the inclusion of partially effective escape mutations in the model can reproduce the diverse patterns of intra-epitope escape that are routinely observed in HIV infected patients. During the majority of escape mutations that have been studied with time-resolved viral sequencing, 2–10 distinct epitope sequences grow in number to replace the transmitted sequence and eventually one mutant epitope spreads to the entire population. Furthermore, the dominant mutated epitope sequence changes over time <xref ref-type="bibr" rid="pcbi.1003878-Liu2">[11]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Goonetilleke1">[30]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Fischer1">[31]</xref>. Although, in some epitopes, mutations are added at new sites in a nested fashion, in a larger number of epitopes, mutations at new sites replace mutations at previous sites leading to a non-nested pattern. This pattern is atypical for models assuming constant selection pressure. The analysis below illustrates how time-dependent selection due to the changing CTL pressure and partial CTL recognition loss can produce the non-nested pattern of escape (see <xref ref-type="bibr" rid="pcbi.1003878-Rouzine2">[32]</xref> for review).</p>
</sec><sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Phases of HIV infection</title>
<p>In order to study escape from the immune response we consider a model that includes target cells, infected cells and multiple CTL clones which recognize regions in the viral genome (epitopes) with equal avidities (<xref ref-type="fig" rid="pcbi-1003878-g001">Figure 1A</xref> and <xref ref-type="sec" rid="s4"><italic>Materials and Methods</italic></xref>). The model predicts three distinct phases of HIV infection (<xref ref-type="fig" rid="pcbi-1003878-g001">Figure 1B</xref>), as follows. Phase 1: The transmitted HIV strain expands in the population of target cells. Phase 2: All CTL clones that recognize cells infected by the transmitted strain are activated, expand, and reduce the number of infected cells. A steady state is obtained with constant levels of infected cells and CTL, which represents chronic HIV infection (see Equations S1–S3). Phase 3: Escape mutations in viral epitopes emerge, changing the genetic composition of the population of infected cells and the clonal composition of the CTL population but only weakly affecting their overall sizes.</p>
<fig id="pcbi-1003878-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003878.g001</object-id><label>Figure 1</label><caption>
<title>A computational model of the interaction between HIV and multiple CTL clones.</title>
<p>(A) The model given by <xref ref-type="disp-formula" rid="pcbi.1003878.e114">Equations 6</xref> to <xref ref-type="disp-formula" rid="pcbi.1003878.e116">8</xref> comprises three interacting cell compartments: target cells (T), infected cells (I) and multiple CTL clones (E). Viral genomes contain multiple epitopes, which can mutate to partially abrogate CTL recognition. An escape mutation is denoted by an X. Each CTL clone recognizes a single viral epitope and is stimulated to divide at a rate proportional to the number of infected cells with recognizable epitopes. The model is designed to study the rate of escape in epitopes when CTL pressure is distributed across multiple epitopes, as well as study intra-epitope escape patterns when CTL respond dynamically to the infected cells that they recognize. Black arrows: flux of cells from one compartment to another. Blue arrows: dependence of the rate of flux from one compartment on another. Dotted lines represent attenuation of the interaction strength. (B) Simulation example showing three phases of HIV evolution. A single virus strain initiates the infection (transmitted strain, black). In response to the growing number of infected cells, multiple CTL clones are activated (colored lines), and the system reaches a steady state. Finally, virus strains with escape mutations (dashed, colored lines) replace the transmitted strain. In response to lowered activation signals, some CTL clones decline. The escape strains are colored to match the CTL against which an escape was most recently acquired. Model parameters: number of epitopes, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e006" xlink:type="simple"/></inline-formula>; number of sites per epitope, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e007" xlink:type="simple"/></inline-formula>. Epitopes 1–3 have parameters that allow escape <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e008" xlink:type="simple"/></inline-formula>, epitopes 4–6 have parameters that prohibit escape, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e009" xlink:type="simple"/></inline-formula>. Other parameters are listed in <xref ref-type="table" rid="pcbi-1003878-t001">Table 1</xref>.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003878.g001" position="float" xlink:type="simple"/></fig>
<p>The dynamics of infected cells and CTL during the escape phase (Phase 3) depends on the number of epitopes that are targeted, <italic>n</italic>, and on the degree of recognition loss per mutation, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e010" xlink:type="simple"/></inline-formula> (<xref ref-type="table" rid="pcbi-1003878-t001">Table 1</xref>). In the simplest case, if a single CTL clone is present in steady state and an escape mutation arises which completely abrogates CTL recognition (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e011" xlink:type="simple"/></inline-formula>), the CTL clone contracts and the population of infected cells containing the escape mutation grows uncontrolled until target cells are depleted (whether and for how long the escape mutation is maintained after disappearance of the CTL clone depends on the fitness cost of the mutation). In contrast, if the recognition loss conferred by the escape mutation is partial (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e012" xlink:type="simple"/></inline-formula>), the population of infected cells grows only transiently, and the CTL clone expands until a new steady state is reached. When a group of CTL clones with similar avidity target the infected cell population (as shown in <xref ref-type="fig" rid="pcbi-1003878-g001">Figure 1B</xref>), the spread of either partly or fully effective escape mutation causes the corresponding CTL clone to contract, since it recognizes infected cells less efficiently than other CTL clones (see Equation S5). Because infected cells continue to be recognized by other CTL clones, the population of infected cells does not grow out of control following the escape mutation. Thus, the model reproduces the three-phase dynamics that can be inferred from kinetic data in HIV infected individuals including the waning of CTL responses to escaped epitopes <xref ref-type="bibr" rid="pcbi.1003878-Liu2">[11]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Henn1">[13]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Goonetilleke1">[30]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Fischer1">[31]</xref>.</p>
<table-wrap id="pcbi-1003878-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003878.t001</object-id><label>Table 1</label><caption>
<title>Model parameters.</title>
</caption><alternatives><graphic id="pcbi-1003878-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003878.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Parameter</td>
<td align="left" rowspan="1" colspan="1">Realistic Value</td>
<td align="left" rowspan="1" colspan="1">Description</td>
<td align="left" rowspan="1" colspan="1">Reference</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>n</italic></td>
<td align="left" rowspan="1" colspan="1">1–8</td>
<td align="left" rowspan="1" colspan="1">Number of epitopes recognized during first 100 days</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003878-Liu2">[11]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Henn1">[13]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Goonetilleke1">[30]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Fischer1">[31]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>m</italic></td>
<td align="left" rowspan="1" colspan="1">2–10</td>
<td align="left" rowspan="1" colspan="1">Number of sites per epitope important for recognition</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003878-Liu2">[11]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Henn1">[13]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Goonetilleke1">[30]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Fischer1">[31]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e013" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">1 <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e014" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Rate at which activated target cells transition out of the highly infectable phase</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003878-Kuroda1">[46]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Li1">[68]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e015" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e016" xlink:type="simple"/></inline-formula> cells</td>
<td align="left" rowspan="1" colspan="1">Activated target cell level</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003878-Sergeev1">[47]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Kuroda2">[69]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Ogg2">[70]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e017" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">1 <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e018" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Virus-induced infected cell death rate</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003878-Klatt1">[55]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e019" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">4 <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e020" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">CTL-induced infected cell death rate</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003878-Sergeev1">[47]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Kuroda2">[69]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Ogg2">[70]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>β</italic></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e021" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Basic efficiency of target cell infection</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003878-Sergeev1">[47]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Kuroda2">[69]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Ogg2">[70]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>s</italic></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e022" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Intrinsic mutation cost</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003878-Troyer1">[10]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Song1">[21]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Boutwell1">[22]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Schneidewind1">[27]</xref>–<xref ref-type="bibr" rid="pcbi.1003878-Matthews1">[29]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>α</italic></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e023" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Reduction of CTL recognition</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003878-Schneidewind1">[27]</xref>–<xref ref-type="bibr" rid="pcbi.1003878-Matthews1">[29]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e024" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e025" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Fractional reduction in intrinsic replication rate</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e026" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e027" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Fractional reduction of CTL recognition</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e028" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e029" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">CTL killing efficiency. Gives <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e030" xlink:type="simple"/></inline-formula> CTLs in chronic infection</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003878-Ogg1">[45]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e031" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e032" xlink:type="simple"/></inline-formula> cells</td>
<td align="left" rowspan="1" colspan="1">Initial population of CTLs</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003878-Kuroda2">[69]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>c</italic></td>
<td align="left" rowspan="1" colspan="1">1 <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e033" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Maximum growth rate of effector cells</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003878-Kuroda2">[69]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e034" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">0.1 <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e035" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Death rate of effector cells</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003878-Sergeev1">[47]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Kuroda2">[69]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Ogg2">[70]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e036" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e037" xlink:type="simple"/></inline-formula> cells</td>
<td align="left" rowspan="1" colspan="1">Number of recognized infected cells for half maximal proliferation of CTL (inverse avidity). Gives an infected cell level of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e038" xlink:type="simple"/></inline-formula> in chronic infection</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pcbi.1003878-Haase1">[44]</xref></td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label/><p>Model parameters for the model of escape from multiple CTL shown in <xref ref-type="fig" rid="pcbi-1003878-g001">Figure 1</xref>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b">
<title>The escape rate of a mutant strain is determined by the loss of CTL recognition and the loss of viral fitness</title>
<p>Escape mutations begin to be selected once CTL reach sufficiently high levels (third phase in <xref ref-type="fig" rid="pcbi-1003878-g001">Figure 1B</xref>). Mutations in all targeted epitopes begin to grow simultaneously, albeit with different rates due to variation in the amounts of fitness and recognition losses caused by a mutation. The exponential growth rates (escape rates) of mutant strains determine which mutant strain will grow to dominate the population. Here we describe the growth of a mutated strain (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e039" xlink:type="simple"/></inline-formula>) with a single mutation in epitope 1. An escape mutation results in both a fractional fitness cost, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e040" xlink:type="simple"/></inline-formula>, and a fractional loss of CTL recognition, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e041" xlink:type="simple"/></inline-formula>. The mutant strain begins to grow as <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e042" xlink:type="simple"/></inline-formula>, with initial growth rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e043" xlink:type="simple"/></inline-formula>: <disp-formula id="pcbi.1003878.e044"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003878.e044" xlink:type="simple"/><label>(1)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e045" xlink:type="simple"/></inline-formula> is the fraction of CTL population recognizing epitope 1 (see <xref ref-type="disp-formula" rid="pcbi.1003878.e115">Equation 7</xref> in <xref ref-type="sec" rid="s4">Materials and Methods</xref> and <xref ref-type="supplementary-material" rid="pcbi.1003878.s004">Text S1</xref>). Thus, the escape rate reflects the balance between the partial recognition loss and the partial fitness loss, which determines whether a mutant strain has a selective advantage (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e046" xlink:type="simple"/></inline-formula>). In order to infer, for example, the fitness cost of an escape mutation, it is necessary to measure not only the escape rate, but also the CTL recognition loss.</p>
<p>When multiple epitopes are targeted and recognition and fitness losses vary across epitopes, the growth rates of escape mutants vary as well (<xref ref-type="fig" rid="pcbi-1003878-g001">Figure 1B</xref>). In data from HIV infected individuals, it is observed that the rate of escape slows dramatically over the first 100 days post infection <xref ref-type="bibr" rid="pcbi.1003878-Liu2">[11]</xref>–<xref ref-type="bibr" rid="pcbi.1003878-Henn1">[13]</xref>. The rise of escape mutants predicted by the model is consistent with these findings (<xref ref-type="supplementary-material" rid="pcbi.1003878.s001">Figure S1</xref>). Furthermore, assuming only a minor fitness cost, the entire observed variation of escape rates over time and across sites can be simulated from the variation of the recognition loss, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e047" xlink:type="simple"/></inline-formula>.</p>
</sec><sec id="s2c">
<title>The trajectory of escape mutations in the cost-benefit plane (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e048" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e049" xlink:type="simple"/></inline-formula>)</title>
<p>The process of gradual viral escape from the immune response of an infected host continues for years. During this time, the virus shows a limited number of detectable CTL responses against different sites (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e050" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003878-Turnbull2">[33]</xref>) where a total of 5–30 escape mutations are selected <xref ref-type="bibr" rid="pcbi.1003878-Liu2">[11]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Goonetilleke1">[30]</xref>. We investigate the trajectory connecting these escape mutations in the cost-benefit plane and predict how the average fitness costs and recognition losses incurred by an escape mutation will change as escape progresses. For this aim, we use a simplified version of the main model (see <xref ref-type="sec" rid="s4"><italic>Materials and Methods</italic></xref>), focused only on the order of escape mutations (i.e., model dynamics are not considered explicitly). Parameters <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e051" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e052" xlink:type="simple"/></inline-formula> are randomly generated for a genome with multiple epitopes and multiple sites per epitope (10 epitopes, with 10 sites per epitope in <xref ref-type="fig" rid="pcbi-1003878-g002">Figure 2</xref>) and epitope sites are ranked in the descending order of escape rate (<xref ref-type="disp-formula" rid="pcbi.1003878.e044">Equation 1</xref>). When many random runs are compared, a correlation between <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e053" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e054" xlink:type="simple"/></inline-formula> for escape mutations of a given rank is observed (<xref ref-type="fig" rid="pcbi-1003878-g002">Figure 2A</xref>). The average trajectory of escape in the cost-benefit plane moves from high recognition loss, low fitness cost to low recognition loss, high fitness cost. The maximum escape rate per epitope decreases over many rounds of escape (<xref ref-type="fig" rid="pcbi-1003878-g002">Figure 2B</xref>) and each epitope escapes at more than one site. This prediction is consistent with experimental observation, where the majority of escaping epitopes undergo more than one mutation <xref ref-type="bibr" rid="pcbi.1003878-Henn1">[13]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Goonetilleke1">[30]</xref>.</p>
<fig id="pcbi-1003878-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003878.g002</object-id><label>Figure 2</label><caption>
<title>The escape trajectory in the cost-benefit plane bends over time due to CTL decay.</title>
<p>Fitness costs and recognition losses are randomly generated for 100 sites (10 epitopes with 10 sites per epitope) in order to study the sequence of escaped sites (black line) in the whole genome without CTL decay (A,B) or with CTL decay (C,D) for 1000 simulation runs. (A) For each site that escapes, the fractional fitness cost, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e055" xlink:type="simple"/></inline-formula>, multiplied by the number of epitopes, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e056" xlink:type="simple"/></inline-formula>, and fractional recognition loss, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e057" xlink:type="simple"/></inline-formula> (<xref ref-type="disp-formula" rid="pcbi.1003878.e044">Equation 1</xref> and <xref ref-type="table" rid="pcbi-1003878-t001">Table 1</xref>) is shown. Colors show the predicted rank of escape mutations, from early escape mutations (blue) to late escape mutations (red). The average trajectory over all runs (black) moves from high recognition loss, low fitness cost to low recognition loss, high fitness cost. Inset: The best-fit slope for each escape rank. A positive correlation is observed between the fitness and recognition losses for all epitopes that escape at a given rank. (B) The maximum escape rate of any epitope site for all 10 epitopes for a representative simulation run. (C–D) As in (A–B), except including CTL decay. CTL decay is simulated by reducing recognition losses for all epitope sites in epitopes that have partially escaped according to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e058" xlink:type="simple"/></inline-formula>, summing over all <italic>i</italic> sites in the epitope that have escaped with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e059" xlink:type="simple"/></inline-formula> per escape. When CTLs decay in response to an escape in an epitope, the immune pressure on all other sites in that epitope is decreased. The result is that the average trajectory in the cost-benefit plane bends towards the horizontal axis.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003878.g002" position="float" xlink:type="simple"/></fig>
<p>The dynamic interplay between CTL and partially effective escape mutations shape the overall course of HIV escape. As mentioned above, an escape mutation results in the decay of the cognate CTL population. In turn, the CTL decay causes the potential benefit of other escape mutations in the escaping epitope to decrease, because the overall CTL pressure on the epitope is lessened. The presence or absence of CTL decay has observable consequences for the trajectory of escape mutations in the cost-benefit plane. Without the CTL decay, the average slope of the trajectory stays constant over time until no more escapes are possible (<xref ref-type="fig" rid="pcbi-1003878-g002">Figure 2A</xref>). In contrast, when CTL clones decay in response to the recognition loss, the trajectory bends towards <italic>X</italic>-axis (<xref ref-type="fig" rid="pcbi-1003878-g002">Figure 2C</xref>) as early escape in an epitope causes escape mutations on the other sites in that epitope to become progressively less advantageous. Therefore, the total number of escape mutations decreases when CTL decay is included (from 55 in <xref ref-type="fig" rid="pcbi-1003878-g002">Figure 2A</xref> to 20 in <xref ref-type="fig" rid="pcbi-1003878-g002">Figure 2</xref>), which is the result of fewer escape mutations per epitope (fewer steps in <xref ref-type="fig" rid="pcbi-1003878-g002">Figure 2D</xref> compared to <xref ref-type="fig" rid="pcbi-1003878-g002">Figure 2B</xref>).</p>
</sec><sec id="s2d">
<title>Weak correlation between <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e060" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e061" xlink:type="simple"/></inline-formula> has been observed in the <italic>Pol</italic> gene</title>
<p>The simulation example in <xref ref-type="fig" rid="pcbi-1003878-g002">Figure 2</xref> offers an interpretation of the work by Mostowy et al <xref ref-type="bibr" rid="pcbi.1003878-Mostowy2">[26]</xref>, where a weak but statistically significant correlation was observed between fitness costs and HLA binding losses in clinically derived Pol sequences. The existence of the correlation follows from <xref ref-type="disp-formula" rid="pcbi.1003878.e044">Equation 1</xref>, which states that more costly mutations will not appear unless they confer a large benefit to the virus. The model relates the weak strength of the correlation (slope  = −0.12 between the fitness decrease and the impairment of HLA binding) to the large number of active epitopes. The existence of the CTL decay caused by escape can further reduce the slope: mutations sampled during the acute phase of HIV infection are predicted to have a much larger slope than those sampled during the chronic phase (<xref ref-type="fig" rid="pcbi-1003878-g003">Figure 3B</xref>). Since the majority of database sequences used in the cited work fall into the latter category, the small slope of the correlation observed can partially be caused by CTL decay.</p>
<fig id="pcbi-1003878-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003878.g003</object-id><label>Figure 3</label><caption>
<title>Fitness loss and recognition losses of escape mutations are predicted to correlate positively, with a slope that deceases in time.</title>
<p>Sites are randomly sampled from the simulation described in the caption to <xref ref-type="fig" rid="pcbi-1003878-g002">Figure 2</xref> in order to simulate the effect of acute samples (high ranking sites), late chronic samples (low ranking sites) or patient samples from random times (random ranks). (A) No CTL decay. The slope of the correlation from acute (blue) or late chronic (red) sampled escape mutations is the same, however, it is lower for escape mutations sampled at random times (green). (B) CTL decay causes the slope of the correlation to decrease in time, due to decrease of CTL selection pressure. CTL decay is introduced as described in the caption to <xref ref-type="fig" rid="pcbi-1003878-g002">Figure 2</xref> and <italic>Model</italic>.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003878.g003" position="float" xlink:type="simple"/></fig>
<p>There is an important caveat which must be considered when comparing the model with the cited work <xref ref-type="bibr" rid="pcbi.1003878-Mostowy2">[26]</xref>. Loss of CTL recognition in the model is given by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e062" xlink:type="simple"/></inline-formula>, which is a composite parameter comprising changes in antigen processing, presentation and recognition, whereas Mostowy et al use the computationally predicted loss of HLA-epitope binding, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e063" xlink:type="simple"/></inline-formula>. To convert the units, we analyzed data from several publications in which both overall loss of CTL recognition as well as HLA binding impairment was measured <xref ref-type="bibr" rid="pcbi.1003878-Schneidewind1">[27]</xref>–<xref ref-type="bibr" rid="pcbi.1003878-Matthews1">[29]</xref>. We found a strong correlation between <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e064" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e065" xlink:type="simple"/></inline-formula> expressed as a linear relationship <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e066" xlink:type="simple"/></inline-formula> (<xref ref-type="supplementary-material" rid="pcbi.1003878.s002">Figure S2</xref>, Equations S10–S14), which justifies our comparison between the model predictions and this data.</p>
</sec><sec id="s2e">
<title>Three patterns of antigenic escape in an epitope with two sites</title>
<p>Epitopes with many sites can produce different combinations of escape mutations (haplotypes) in response to CTL pressure. In <xref ref-type="bibr" rid="pcbi.1003878-Goonetilleke1">[30]</xref> it was observed that the mutated sequence changed over time in the majority of epitopes that were studied longitudinally and, interestingly, the order in which escape haplotypes appeared varied from epitope to epitope. We divide the epitopes into three characteristic patterns, based on the order of dominant haplotypes: “simple”, “nested” and “leapfrog”. We can illustrate these patterns in an epitope with two sites, in which four haplotypes are possible. The presence or absence of an escape mutation at each site is denoted by a 1 or a 0, respectively. The infrequently observed “simple” pattern is characterized by a single escape haplotype. For example, in an epitope with two sites, the sequence of haplotypes observed is <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e067" xlink:type="simple"/></inline-formula>. The “nested” escape adds a new mutation sequentially to a previously mutated sequence: <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e068" xlink:type="simple"/></inline-formula>. This pattern is predicted if mutations at both sites are under a constant, positive selection pressure (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e069" xlink:type="simple"/></inline-formula> throughout the course of infection). The “leapfrog” pattern is characterized by a switch in the dominant single-site mutation: <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e070" xlink:type="simple"/></inline-formula>. In the present model, the leapfrog pattern of escape arises due to time-dependent CTL selection pressure. Below we use the model to determine the distribution of fitness and recognition losses within an epitope that produces the leapfrog pattern of escape.</p>
<p>In order to study intra-epitope dynamics, we use the main model (<xref ref-type="disp-formula" rid="pcbi.1003878.e114">Equations 6</xref> to <xref ref-type="disp-formula" rid="pcbi.1003878.e116">8</xref>) and consider a genome composed of a large number of two-site epitopes. This simple case can be studied in detail, and the results can illustrate the general case, where epitopes are comprised of many sites. We use <xref ref-type="disp-formula" rid="pcbi.1003878.e044">Equation 1</xref> to determine the escape rates for each of the three mutant haplotypes has for a given level of CTL clone <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e071" xlink:type="simple"/></inline-formula> recognizing epitope <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e072" xlink:type="simple"/></inline-formula>:<disp-formula id="pcbi.1003878.e073"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003878.e073" xlink:type="simple"/><label>(2)</label></disp-formula><disp-formula id="pcbi.1003878.e074"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003878.e074" xlink:type="simple"/><label>(3)</label></disp-formula><disp-formula id="pcbi.1003878.e075"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003878.e075" xlink:type="simple"/><label>(4)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e076" xlink:type="simple"/></inline-formula> is the time dependent fraction of the total CTL population comprised by CTL clone <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e077" xlink:type="simple"/></inline-formula> and we have neglected the small parameter <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e078" xlink:type="simple"/></inline-formula> (<xref ref-type="table" rid="pcbi-1003878-t001">Table 1</xref>). We consider the case where the initial escape rate of haplotype 10 in epitope <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e079" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e080" xlink:type="simple"/></inline-formula>) is higher than the initial escape rate of haplotype 01 (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e081" xlink:type="simple"/></inline-formula>).</p>
<p>Once an escape haplotype has reached a sufficiently high frequency, CTL clone <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e082" xlink:type="simple"/></inline-formula> will decay monotonically in time, but the virus load will stay stable, since the population of infected cells will be controlled by the other CTL clones. As <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e083" xlink:type="simple"/></inline-formula> decreases and the CTL-induced pressure on the epitope declines, the fitness losses at the two sites, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e084" xlink:type="simple"/></inline-formula>, begin to dominate the escape rates (<xref ref-type="disp-formula" rid="pcbi.1003878.e073">Equations 2</xref>–<xref ref-type="disp-formula" rid="pcbi.1003878.e075">4</xref>), and the favored haplotype will change. Eventually, the decay of the CTL clone will cause the transmitted haplotype (00) to regain fitness advantage and become a dominant strain again (the existence of compensatory mutations may cause stabilization of the last escaped clone, see <xref ref-type="sec" rid="s3"><italic>Discussion</italic></xref>). The sequence of dominant haplotypes can follow one of the patterns, as follows:</p>
<sec id="s2e1">
<title>Simple pattern</title>
<p>The simple pattern of escape (<xref ref-type="fig" rid="pcbi-1003878-g004">Figure 4A</xref>) can occur if the second site cannot escape (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e085" xlink:type="simple"/></inline-formula>, <xref ref-type="disp-formula" rid="pcbi.1003878.e074">Equation 3</xref>). It can also occur if the second site is weakly advantageous, yet the double mutant (11) does not have time to grow to appreciable frequency before the transmitted haplotype (00) regains the advantage in growth rate. Observation of this pattern implies a large difference in the fitness costs and/or recognition loss magnitudes between the two sites in an epitope.</p>
<fig id="pcbi-1003878-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003878.g004</object-id><label>Figure 4</label><caption>
<title>Dynamical selection pressure from CTLs causes three possible patterns of intra-epitope escape: Example for an epitope with two sites.</title>
<p>Intra-epitope escape in one epitope with two sites is studied for the model shown in <xref ref-type="fig" rid="pcbi-1003878-g001">Figure 1</xref> and <italic>Model</italic>. The sequence in which haplotypes are selected depends on the distribution of fitness and recognition losses within an epitope. The fraction of the infected cell population containing each of the four haplotypes in the escaping epitope is shown in “simple” (A), “leapfrog” (C) and “nested” pattern (E). For each pattern, the dependence of the escape rate (<xref ref-type="disp-formula" rid="pcbi.1003878.e073">Equations 2</xref>–<xref ref-type="disp-formula" rid="pcbi.1003878.e075">4</xref>) for each haplotype on the fraction of CTLs responding to the epitope (B, D, F). The inset shows CTL dynamics: the size of the CTL clone to escaping epitope (red) and the total CTL number (black). Parameters: (A,B) <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e086" xlink:type="simple"/></inline-formula>, (C,D) <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e087" xlink:type="simple"/></inline-formula>, (E,F) <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e088" xlink:type="simple"/></inline-formula> with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e089" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e090" xlink:type="simple"/></inline-formula> for all panels; other parameters are given in <xref ref-type="table" rid="pcbi-1003878-t001">Table 1</xref>.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003878.g004" position="float" xlink:type="simple"/></fig></sec><sec id="s2e2">
<title>Leapfrog pattern</title>
<p>The leapfrog pattern can occur if haplotype 01 gains the advantage over 10 before the 10 loses the advantage over 00 (<xref ref-type="fig" rid="pcbi-1003878-g004">Figure 4C and D</xref>). In order for this to occur, site 1 must have both a greater fitness and a greater recognition loss than site 2: <disp-formula id="pcbi.1003878.e091"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003878.e091" xlink:type="simple"/><label>(5)</label></disp-formula></p>
<p>The CTL clone to the escaping epitope decays at a faster rate during the time period when variant 10 dominates the population than than during the period when 01 dominates the population. The difference is due to the relatively higher recognition loss of the mutation at the first site (inset <xref ref-type="fig" rid="pcbi-1003878-g004">Figure 4D</xref>). The exact conditions required for this pattern are given in <xref ref-type="supplementary-material" rid="pcbi.1003878.s006">Text S3</xref>.</p>
</sec><sec id="s2e3">
<title>Nested pattern</title>
<p>When both single-mutant haplotypes continue to have a positive growth rate throughout the course of infection, as in the case of constant selection pressure, the double-mutant haplotype has the highest escape rate (<xref ref-type="fig" rid="pcbi-1003878-g004">Figure 4E, F</xref>). The nested pattern may occur if the escape rates of both single-mutant haplotypes are similar (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e092" xlink:type="simple"/></inline-formula>).</p>
<p>We use numeric computation to determine which pattern of escape is observed over a range of recognition and fitness losses at each of the two epitope sites. The number of epitopes is fixed, <italic>n</italic>, the escape rate for the first haplotype, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e093" xlink:type="simple"/></inline-formula>, and the ratio of the fitness costs in the two epitope sites, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e094" xlink:type="simple"/></inline-formula>, at values that are representative of acute infection (<xref ref-type="fig" rid="pcbi-1003878-g005">Figure 5</xref>) or chronic infection (<xref ref-type="supplementary-material" rid="pcbi.1003878.s003">Figure S3</xref>) (see <xref ref-type="supplementary-material" rid="pcbi.1003878.s001">Figure S1</xref> for the range of escape rates observed in HIV infected patients). For large escape rates, the leapfrog pattern can be observed for large values of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e095" xlink:type="simple"/></inline-formula> and a broad range of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e096" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1003878-g005">Figure 5</xref>). Smaller values of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e097" xlink:type="simple"/></inline-formula> produce smaller escape rates, and the leapfrog is observed in a narrow range of small <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e098" xlink:type="simple"/></inline-formula> (<xref ref-type="supplementary-material" rid="pcbi.1003878.s003">Figure S3</xref>). In some cases, haplotype 11 is observed as a short intermediate between haplotypes 10 and 01 (labeled “nested leapfrog” in <xref ref-type="fig" rid="pcbi-1003878-g005">Figure 5</xref>). The time interval during which a given haplotype dominates the population depends on parameters of loss and recognition at epitope site, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e099" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e100" xlink:type="simple"/></inline-formula>. The less costly haplotype can dominate the population for months to years (shown as <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e101" xlink:type="simple"/></inline-formula> in the inset of Figures AS3 and <xref ref-type="fig" rid="pcbi-1003878-g005">Figure 5</xref>). CTL to the escaping epitope will decay at the fastest rate when variant 11 dominates the population (inset <xref ref-type="fig" rid="pcbi-1003878-g004">Figure 4F</xref>).</p>
<fig id="pcbi-1003878-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003878.g005</object-id><label>Figure 5</label><caption>
<title>The pattern of emergence of escape variants in a single epitope contains information about the fraction of recognition and fitness lost by single-site mutations in the epitope.</title>
<p>Using simulation of the model (<xref ref-type="fig" rid="pcbi-1003878-g001">Figure 1A</xref>, <xref ref-type="disp-formula" rid="pcbi.1003878.e114">Equations 6</xref> to <xref ref-type="disp-formula" rid="pcbi.1003878.e116">8</xref>) with two sites per epitope, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e102" xlink:type="simple"/></inline-formula>, the pattern of escape is calculated for a range of recognition and fitness losses. The pattern that is obtained is plotted as a function of the parameters of recognition loss at the first and second site (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e103" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e104" xlink:type="simple"/></inline-formula>, respectively). In each panel, certain parameters are fixed in order to focus on the effect of recognition loss. Fixed parameters are: the escape rate of the first haplotype (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e105" xlink:type="simple"/></inline-formula>) and the number of targeted epitopes (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e106" xlink:type="simple"/></inline-formula>), values which correspond to escape mutations that occur in acute infection (see <xref ref-type="supplementary-material" rid="pcbi.1003878.s003">Figure S3</xref> for parameters that correspond to later in infection). Fitness costs are chosen such that the second site is less costly than the first: <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e107" xlink:type="simple"/></inline-formula> equal to 3 (A) or much less costly than the first, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e108" xlink:type="simple"/></inline-formula> (B). Other parameters given in <xref ref-type="table" rid="pcbi-1003878-t001">Table 1</xref>. Mostowy: 2012iv Equations S6 (red line) and S9 (blue line) determine the region where the leapfrog pattern can be observed. Regions that require <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e109" xlink:type="simple"/></inline-formula> are not allowed by definition (magenta line). The shaded regions between these three lines correspond to regions of parameter space where both sites escape. The corresponding patterns are: “leapfrog” (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e110" xlink:type="simple"/></inline-formula>, <xref ref-type="fig" rid="pcbi-1003878-g004">Figure 4C</xref>), “nested” (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e111" xlink:type="simple"/></inline-formula>, <xref ref-type="fig" rid="pcbi-1003878-g004">Figure 4E</xref>), “nested leapfrog” (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e112" xlink:type="simple"/></inline-formula>). Observation of the leapfrog pattern in an epitope tightly constrains the fraction of CTL recognition loss conferred by sites in an epitope. The inset shows the length of time during which haplotype 01 is dominant in the escaping epitope.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003878.g005" position="float" xlink:type="simple"/></fig></sec></sec></sec><sec id="s3">
<title>Discussion</title>
<p>The recent availability of time-resolved, deep-sequencing data from HIV infected patients have illuminated the complexity of interaction between CTL clones and the genetically diverse HIV population. Using a model including multiple CTL clones, we demonstrate that the rate of viral escape depends on both the partial recognition losses and fitness costs associated with an escape mutation as well as the number of active CTL clones. Furthermore, the model predicts that CTL populations change their relative sizes in response to viral escape, which has observable consequences for the sequence and number of escape mutations that are possible over time. Changing selection pressure on an epitope due to declining CTL levels can also cause the dominant escape variant in an epitope to change in a non-nested fashion. The model contains several assumptions and simplifications, as follows.</p>
<sec id="s3a">
<title>Pre-existing mutations</title>
<p>We assume that the population of infected cells in acute infection and steady state is large, so that all single escape mutants exist in the population before the rise of CTL (as in <xref ref-type="bibr" rid="pcbi.1003878-Althaus1">[14]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Mostowy1">[15]</xref>). The assumption is supported by estimates of the large effective HIV population size <xref ref-type="bibr" rid="pcbi.1003878-Rouzine1">[4]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Kouyos1">[34]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Pennings1">[35]</xref>. We can also infer the fact of preexistence of CTL escape mutations from the observed preexistence of drug-resistant mutations evident in the early emergence of resistance to mono-therapy (e.g. <xref ref-type="bibr" rid="pcbi.1003878-Richman1">[36]</xref>). Furthermore, since the number of escape mutations per epitope is typically larger than the number of drug resistance sites per drug, the mutation cost of the least costly escape mutation can be assumed to be lower – and the frequency of preexisting mutations higher – for escape mutations. The preexistence of single mutants casts doubts on the interpretation of very late escape mutations as the result of the late appearance of an escape mutation not initially present in the population <xref ref-type="bibr" rid="pcbi.1003878-Liu4">[37]</xref>.</p>
</sec><sec id="s3b">
<title>Eventual reversion to the wild type is prevented by compensatory mutations</title>
<p>Mutations compensating for fitness losses were documented for drug-resistance mutations (e.g. <xref ref-type="bibr" rid="pcbi.1003878-QuionesMateu1">[38]</xref>–<xref ref-type="bibr" rid="pcbi.1003878-Hinkley1">[40]</xref>) and for immune-escape mutations <xref ref-type="bibr" rid="pcbi.1003878-Troyer1">[10]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Kelleher1">[19]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Crawford1">[20]</xref> (For an overview of compensatory mutations in HIV see <xref ref-type="bibr" rid="pcbi.1003878-Poon1">[41]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Rouzine3">[42]</xref>). However, the dynamics of compensation remains poorly understood. Therefore, our model does not explicitly include compensatory mutations and, as a result, predicts the eventual reversion of any escape mutation with a fitness cost. Instead of including compensation, we calculate the period of time that a given mutation would be maintained in the population before reversion occurs, which is the same time interval where compensation would be necessary in order to prevent reversion (inset of <xref ref-type="fig" rid="pcbi-1003878-g005">Figures 5</xref> and <xref ref-type="supplementary-material" rid="pcbi.1003878.s003">S3</xref>). When the non-nested pattern of escape is observed in infected patients, the first escape variant is typically short-lived compared to the second escape variant, and the transmitted variant is not observed after the initial escape <xref ref-type="bibr" rid="pcbi.1003878-Liu2">[11]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Goonetilleke1">[30]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Fischer1">[31]</xref>. Our interpretation is that the fitness cost of the first variant is large relative to the second variant and does not have time to be compensated before the second variant gains the advantage. The second variant either has a very small fitness cost or is compensated gradually during its lifetime (compensation is not explicitly simulated). Our calculation of the lifetimes of different escape variants in an epitope is a first step towards understanding the timescales associated with compensation.</p>
</sec><sec id="s3c">
<title>Multiple CTL clones of equal avidity</title>
<p>The present analysis is focused on the first year post-infection, the time interval in which most escape mutations occur. Therefore, we consider a group of CTL clones with similar avidities that are present initially in similar numbers. This is a reasonable assumption after escape mutations have occured in the first few immunodominant epitopes during the resolution of acute viremia. At this time, a large number of CTL clones are activated and are maintained for many months at simular levels <xref ref-type="bibr" rid="pcbi.1003878-Karlsson1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Turnbull2">[33]</xref>. Once all CTL clones are activated, our model predicts that the steady state viral load is proportional to the inverse avidity of the most avid CTL clone (Equation S2). Kadolsky and Asquith <xref ref-type="bibr" rid="pcbi.1003878-Kadolsky1">[43]</xref> estimated that the average viral load increases by only 0.051 log copies/ml per CTL escape. This small increase, which we interpret to be the average difference avidity spacing between CTL clones, justifies our assumption that CTL avidities are, indeed, very closely spaced. Our analysis shows that, given closely spaced avidities, it is recognition and fitness losses that govern the order and timing of escape mutations, rather than variation in CTL avidity.</p>
</sec><sec id="s3d">
<title>Other assumptions</title>
<p>The model includes additional simplifying assumptions, as follows. i) The proliferation rate of CTL clones saturates with the infected cell number, but not with the total CTL level. In the original model <xref ref-type="bibr" rid="pcbi.1003878-Althaus1">[14]</xref>, the authors postulate that the total number of CTL limits the growth of individual CTL clones, which causes clones to interact and enables the co-existence of multiple CTL clones with different avidities. We believe that further study is needed to verify the existence and the possible origin of the interclonal interaction. (Note that the target availability may not be the cause of interclonal interaction, because most CTL are not bound to their targets even at the peak of infection, and the overall effector to target ratio is less than two <xref ref-type="bibr" rid="pcbi.1003878-Haase1">[44]</xref>.) ii) CTL are short-lived in the absence of antigen, with an average lifetime of 10 days, as is consistent with early studies of CTL dynamics in SIV system <xref ref-type="bibr" rid="pcbi.1003878-Ogg1">[45]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Kuroda1">[46]</xref> and mathematical modeling of these data <xref ref-type="bibr" rid="pcbi.1003878-Sergeev1">[47]</xref>. iii) We ignore recombination, which may increase the rate of emergence of escape mutations among different epitopes <xref ref-type="bibr" rid="pcbi.1003878-Mostowy1">[15]</xref> as well as the long term rate of evolution <xref ref-type="bibr" rid="pcbi.1003878-Batorsky1">[48]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Neher1">[49]</xref>. For the intra-epitope dynamics of escape, recombination between neighboring sites will be a small correction. (iv) CTL clones against escape mutants are not included in the model. By including partial rather than full recognition loss, we allow CTL to escaped epitopes to continue to exert selection pressure without incorporating additional CTL clones. Though clones to escape mutants may exist, introducing extra CTL clones (5 clones for each two-site epitope, instead of 1) would complicate analysis of the model without changing the essential results. (v) Small fitness costs are assumed. <xref ref-type="disp-formula" rid="pcbi.1003878.e044">Equation 1</xref> states that costly escapes <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e113" xlink:type="simple"/></inline-formula> cannot arise when recognition losses are partial and many CTL clones target the viral genome. We choose to focus on the time interval corresponding to the first year after the resolution of acute infection when these assumptions are fulfilled. Escape mutations entailing a high fitness cost can only escape when only one or two CTL clones dominate strongly, which we estimate from previous data to be during the 3–4 weeks post-infection. (vi) Fitness costs are positive. A fraction of mutations that are transmitted to an individual that fall outside the individuals HLA-restricted epitopes revert (i.e. may have a negative fitness cost). However, the rate of reversion is very small <xref ref-type="bibr" rid="pcbi.1003878-Kearney1">[17]</xref> and hardly interferes with the faster dynamics of within-epitope mutations. (vii) We consider escape processes in different epitopes separately, because typically they do not overlap much in time. In general, however, linkage effects (clonal interference, background selection) between epitope mutations and compensatory mutations of same or different epitopes may complicate the picture (see <xref ref-type="bibr" rid="pcbi.1003878-Rouzine2">[32]</xref> for review of recent research in this area).</p>
<p>Thus, our model has demonstrated that partial recognition losses, in addition to fitness costs and the breadth of the CTL response, dramatically affect the rate and the order of escape mutations during an HIV infection. These findings help to interpret the positive correlation between fitness costs and recognition losses observed in the Pol gene <xref ref-type="bibr" rid="pcbi.1003878-Mostowy2">[26]</xref> and make the testable prediction that the strength of the correlation should decrease with the time post-infection. Our results call for direct measurements of recognition losses for different escape mutations. Combined with the proposed trajectory approach (<xref ref-type="fig" rid="pcbi-1003878-g002">Figure 2</xref>), these data will serve as a basis for improved prediction of conserved epitopes for use in vaccines.</p>
</sec></sec><sec id="s4" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s4a">
<title>Model of HIV dynamics</title>
<p>We model SIV/HIV evolution in the presence of multiple CTL clones (<xref ref-type="fig" rid="pcbi-1003878-g001">Figure 1A</xref>). Each CTL clone recognizes a distinct viral epitope that is presented by an infected cell. Mutations occur in the proviral genomes of infected cell that allow an infected cell to partially evade CTL recognition, but come at a cost in terms of viral replication. The model is given by the following equations:<disp-formula id="pcbi.1003878.e114"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003878.e114" xlink:type="simple"/><label>(6)</label></disp-formula><disp-formula id="pcbi.1003878.e115"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003878.e115" xlink:type="simple"/><label>(7)</label></disp-formula><disp-formula id="pcbi.1003878.e116"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003878.e116" xlink:type="simple"/><label>(8)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e117" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e118" xlink:type="simple"/></inline-formula> are the relative viral replication rate of viral genome <italic>i</italic> and the relative CTL recognition of sequence <italic>i</italic> by clone <italic>j</italic>, as compared to the transmitted sequence, respectively:</p>
<p><disp-formula id="pcbi.1003878.e119"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003878.e119" xlink:type="simple"/><label>(9)</label></disp-formula><disp-formula id="pcbi.1003878.e120"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003878.e120" xlink:type="simple"/><label>(10)</label></disp-formula></p>
<p>The processes described are, as follows. Highly infectable target cells (<italic>T</italic>) are replenished at a rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e121" xlink:type="simple"/></inline-formula> cells per day, leave the highly infectable phase with a rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e122" xlink:type="simple"/></inline-formula> and are infected by virus at a rate that depends on the fitness on the infecting strain, with maximum rate per cell <italic>β</italic>, and the number of productively infected cells <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e123" xlink:type="simple"/></inline-formula> in the system. We consider <italic>n</italic> epitopes, each consists of <italic>m</italic> amino acid positions (sites), giving a total of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e124" xlink:type="simple"/></inline-formula> possible strains. An cell infected is labeled by proviral genome <italic>i</italic> with <italic>n</italic> epitopes denoted <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e125" xlink:type="simple"/></inline-formula>, where each epitope, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e126" xlink:type="simple"/></inline-formula>, has <italic>m</italic> sites <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e127" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e128" xlink:type="simple"/></inline-formula> indicates the presence or absence of a mutation at an epitope site. The fitness of genome <italic>i</italic> is reduced by mutations. A mutation in epitope <italic>j</italic> at site <italic>k</italic> contributes cost <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e129" xlink:type="simple"/></inline-formula> to the logarithm of the reduction in replication rate. The strain with all 0 is the transmitted strain, which has fitness 1.</p>
<p>Effector CTL (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e130" xlink:type="simple"/></inline-formula>) are replenished with a constant rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e131" xlink:type="simple"/></inline-formula> cells per day, divide with a rate dependent on the number of infected cells that they recognize and their avidity, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e132" xlink:type="simple"/></inline-formula>, with maximum rate <italic>c</italic>, and die with rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e133" xlink:type="simple"/></inline-formula>. CTL clones each respond to a distinct viral epitope that is presented by an infected cell and kill infected cells at a maximum rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e134" xlink:type="simple"/></inline-formula>. The recognition ability of the CTL clone to epitope <italic>j</italic> in strain <italic>i</italic> is reduced by mutations, as given by <xref ref-type="disp-formula" rid="pcbi.1003878.e120">Equation 10</xref>. A mutation in epitope <italic>j</italic> at site <italic>k</italic> contributes <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e135" xlink:type="simple"/></inline-formula> to the logarithm reduction in CTL recognition. In the present work, we assume CTL of equal avidities, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e136" xlink:type="simple"/></inline-formula>. Throughout the text, we describe the relative loss in fitness and recognition due to escape mutations in terms of notation <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e137" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e138" xlink:type="simple"/></inline-formula>.</p>
<p>Mutations are generated randomly with rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e139" xlink:type="simple"/></inline-formula> per site per generation of infected cells (i.e., the average lifespan of an infected cell, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e140" xlink:type="simple"/></inline-formula>) between strains that differ by one site. Strains with average copy number above one infected cell are simulated deterministically according to the above equations; below this threshold a strain is considered extinct. The basic model with one escape-conferring site per epitope (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e141" xlink:type="simple"/></inline-formula>) has been introduced by Althaus and De Boer <xref ref-type="bibr" rid="pcbi.1003878-Althaus1">[14]</xref>. In this work, we adapt the model to focus on the effect of partial recognition and fitness losses during a narrow time interval after acute infection (see <xref ref-type="sec" rid="s3"><italic>Discussion</italic></xref> for a detailed comparison of the two models). Further information on model parameters and the estimated range of parameter values are listed in <xref ref-type="table" rid="pcbi-1003878-t001">Table 1</xref>. All simulations were performed in Matlab (Mathworks) and the source code can be obtained freely upon request from the authors.</p>
</sec><sec id="s4b">
<title>Killing of infected cells by CTL</title>
<p>Following the original work <xref ref-type="bibr" rid="pcbi.1003878-Althaus1">[14]</xref>, our model assumes that the majority of infected cells are killed by CTL rather than by viral cytopathicity. It has also been proposed that CTL decrease the viral production in infected cells in a non-lytic fashion, by suppressing viral replication, and that cells die within a fixed period of time (∼1 d) due to viral cytopathicity <xref ref-type="bibr" rid="pcbi.1003878-Elemans1">[50]</xref>. A specific choice of the mechanism of viral control does not affect the competition between CTL escape variants (although the long-range nature of the cytokine interaction may slow down the process of escape <xref ref-type="bibr" rid="pcbi.1003878-SeichAlBasatena1">[51]</xref>). However, because there has been considerable controversy on the matter, it deserves a brief discussion.</p>
<p>Two variations of the lytic model have been studied: a simple model in which infected cells are described by a single compartment and a slightly more complex model with two linked compartments of infected cells (cells in the eclipse phase of virion production and cells within a shorter, virus-producing phase). Several authors have argued against single-compartment models for the following reasons: (i) Although viremia and CTL levels vary strongly among patients, the decay rate of viremia under anti-retroviral therapy (ART) (interpreted as the lifespan of infected cells <xref ref-type="bibr" rid="pcbi.1003878-Ho1">[52]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Perelson1">[53]</xref>) is approximately 1 d<sup>−1</sup> with less than 50% variation between patients <xref ref-type="bibr" rid="pcbi.1003878-Markowitz1">[54]</xref>. (ii) The rate of viremia growth under CD8 T cell depletion is 2–3 fold faster than the rate of viremia decay under ART, whereas in the simplest lytic model, the two rates must be the same <xref ref-type="bibr" rid="pcbi.1003878-Jin1">[2]</xref>. (iii) Finally, CD8 depletion does not affect the rate viremia decay rate under ART <xref ref-type="bibr" rid="pcbi.1003878-Klatt1">[55]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Wong1">[56]</xref>. These observations are, however, compatible with two-compartment lytic models <xref ref-type="bibr" rid="pcbi.1003878-Althaus1">[14]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Klenerman1">[57]</xref>–<xref ref-type="bibr" rid="pcbi.1003878-Althaus2">[60]</xref>. In these models the decay rate of viremia under ART is determined by the length of the eclipse phase (lasting ∼1 d), which does not depend on CTL.</p>
<p>Elemans et al <xref ref-type="bibr" rid="pcbi.1003878-Elemans2">[61]</xref> compared the ability of two-compartment lytic models with non-lytic models to explain data in Refs. <xref ref-type="bibr" rid="pcbi.1003878-Klatt1">[55]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Wong1">[56]</xref> and reported that Akaike information criterion generally favors the non-lytic models. However, they conceded that the accuracy of the cited experiments may be insufficient to detect the effect of CD8 T cells. On the other hand, the short duration of the virus-producing phase measured by Wick et al <xref ref-type="bibr" rid="pcbi.1003878-Brodie1">[62]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Wick1">[63]</xref> and a faster decay under ART including an integrase inhibitor compared to therapies including only protease and reverse transcriptase inhibitors <xref ref-type="bibr" rid="pcbi.1003878-Sedaghat1">[59]</xref> support the lytic models with short-lived virus-expressing cells. For these reasons, we choose a lytic model of HIV control (though since we do not aim to predict accurately the viremia decay rate under ART we do not include the eclipse phase). The matter is open to further investigation.</p>
<p>The total CTL killing rate in our model is given by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e142" xlink:type="simple"/></inline-formula> d<sup>−1</sup>, which is higher than assumed in the original work. Elemans et al <xref ref-type="bibr" rid="pcbi.1003878-Elemans1">[50]</xref> reviewed some estimates of the CTL killing rate in a steady state HIV infection. Using antigenic escape data (assuming no mutation cost and full recognition loss), the killing rate was estimated to be 0.1–0.2 d<sup>−1</sup> per CTL response <xref ref-type="bibr" rid="pcbi.1003878-Asquith1">[64]</xref>. Somewhat larger estimates, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e143" xlink:type="simple"/></inline-formula> d<sup>−1</sup> for the total CTL response, were obtained by another indirect method, which compared the death rate of SIV infected cells in animals treated with antiretroviral therapy (ART) between CD8+ depleted and control groups <xref ref-type="bibr" rid="pcbi.1003878-Elemans2">[61]</xref>. The most direct (and highest) estimate, 4–10 d<sup>−1</sup> for the total CTL response, was obtained by Wick et al <xref ref-type="bibr" rid="pcbi.1003878-Brodie1">[62]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Wick1">[63]</xref> who re-infused into patients autologous, <italic>invitro</italic> expanded, CD8+ T cells to 2.5% of total CD8 count. Wick et al then directly quantified the decay rate of virus-expressing cells. The estimate they obtained is 4–10 fold higher than the rate of viremia decay under ART, indicating a short virus producing phase of 2–8 hours. The estimate agrees with those obtained by modeling data from acute SIV infection and HIV dynamics during ART <xref ref-type="bibr" rid="pcbi.1003878-Sergeev1">[47]</xref>, <xref ref-type="bibr" rid="pcbi.1003878-Sergeev2">[65]</xref> and with the killing rate per CTL in acute LCMV infection <xref ref-type="bibr" rid="pcbi.1003878-Ganusov3">[66]</xref> once the difference in CTL level between the two systems is accounted for.</p>
<p>We also introduce the virus-induced infected cell death rate, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e144" xlink:type="simple"/></inline-formula> d<sup>−1</sup>, which is several-fold smaller than the CTL killing rate in steady state <xref ref-type="bibr" rid="pcbi.1003878-Klatt1">[55]</xref>. Parameter <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e145" xlink:type="simple"/></inline-formula> is defined as the inverse length of the highly infectable period of the activated cell cycle, End G1-S-G2-M, which lasts less than 1 day. During that period, a virion entry leads to a successful infection, because the concentrations of nucleotides are maximal, and reverse transcription is completed quickly before HIV RNA is degraded by vigorous innate responses <xref ref-type="bibr" rid="pcbi.1003878-Pan1">[67]</xref>. The choice <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e146" xlink:type="simple"/></inline-formula> over, e.g., <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e147" xlink:type="simple"/></inline-formula> d<sup>−1</sup> (often used as an estimate of the total activated cell lifespan) does not change the dynamics of escape.</p>
</sec><sec id="s4c">
<title>Simplified model to study the order of escape mutations</title>
<p>We introduce a simplified model, which does not explicitly consider dynamics, in order to study the sequence of escape mutations for a realistic size genome. Fractional fitness costs (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e148" xlink:type="simple"/></inline-formula>) and recognition losses (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e149" xlink:type="simple"/></inline-formula>) are randomly generated from a uniform distribution <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e150" xlink:type="simple"/></inline-formula> for 100 sites (10 epitopes with 10 sites per epitope) in order to study the sequence of escaped sites. All sites are ranked in order of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e151" xlink:type="simple"/></inline-formula> and escape sites in similar ranking over many runs are considered together. CTL decay is introduced for all additional sites in an epitope once a site in the epitope escapes: after each round of escape, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e152" xlink:type="simple"/></inline-formula> is reduced for all sites in the epitope by: <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e153" xlink:type="simple"/></inline-formula> for all <italic>i</italic> in the epitope that have escaped. Here parameter <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e154" xlink:type="simple"/></inline-formula> is defined as the decay rate per escape, in contrast to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e155" xlink:type="simple"/></inline-formula> in the main model which is defined per day.</p>
</sec></sec><sec id="s5">
<title>Supporting Information</title>
<supplementary-material id="pcbi.1003878.s001" mimetype="image/tiff" xlink:href="info:doi/10.1371/journal.pcbi.1003878.s001" position="float" xlink:type="simple"><label>Figure S1</label><caption>
<p><bold>Escape rate and </bold><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e156" xlink:type="simple"/></inline-formula><bold> are negatively correlated in two experimental studies.</bold> The frequency of a mutated epitope for epitopes over time is fit to the curve <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e157" xlink:type="simple"/></inline-formula>, which describes deterministic selection on a single site with selection coefficient <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e158" xlink:type="simple"/></inline-formula>, in order to determine parameters <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e159" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e160" xlink:type="simple"/></inline-formula>. Colored dots show data from a single patient studied in <xref ref-type="bibr" rid="pcbi.1003878-Liu2">[11]</xref> (blue) and multiple patients studied in <xref ref-type="bibr" rid="pcbi.1003878-Goonetilleke1">[30]</xref> CH40 (red), CH58 (green), CH77 (cyan). Inset: Simulation example showing the correlation between escape rate, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e161" xlink:type="simple"/></inline-formula>, and the time that the mutation spreads to 50% of the population of infected cells, denoted <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e162" xlink:type="simple"/></inline-formula>. Parameters <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e163" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e164" xlink:type="simple"/></inline-formula> are found for the three escape mutations shown in <xref ref-type="fig" rid="pcbi-1003878-g001">Figure 1B</xref> that occur in the first 200 days post infection. Thus, variation in recognition and fitness losses across many epitopes successfully reproduces this feature of escape dynamics.</p>
<p>(TIF)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003878.s002" mimetype="image/tiff" xlink:href="info:doi/10.1371/journal.pcbi.1003878.s002" position="float" xlink:type="simple"><label>Figure S2</label><caption>
<p><bold>Estimating the relationship between </bold><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e165" xlink:type="simple"/></inline-formula><bold> and </bold><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e166" xlink:type="simple"/></inline-formula><bold> approximately from three published experiments.</bold> Our model contains one parameter for CTL recognition loss caused by a mutation, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e167" xlink:type="simple"/></inline-formula>. In order to compare model predictions with data from Mostowy et al <xref ref-type="bibr" rid="pcbi.1003878-Mostowy2">[26]</xref>, where HLA binding impairment caused by mutations was considered rather than overall CTL recognition loss, we sought to compare HLA binding impairment with overall CTL recognition loss. By combine data from three references, Schneidewind et al <xref ref-type="bibr" rid="pcbi.1003878-Schneidewind1">[27]</xref>, Kawashima et al <xref ref-type="bibr" rid="pcbi.1003878-Kawashima1">[28]</xref> and Matthews et al <xref ref-type="bibr" rid="pcbi.1003878-Matthews1">[29]</xref>, we were able to demonstrate a strong correlation between the two parameters. This justifies our comparison of our model predictions with data from <xref ref-type="bibr" rid="pcbi.1003878-Mostowy2">[26]</xref>.</p>
<p>(TIF)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003878.s003" mimetype="image/tiff" xlink:href="info:doi/10.1371/journal.pcbi.1003878.s003" position="float" xlink:type="simple"><label>Figure S3</label><caption>
<p><bold>CTL lifetime changes the frequency with which intra-epitope escape patterns are observed.</bold> Here we show a modified version of <xref ref-type="fig" rid="pcbi-1003878-g005">Figure 5</xref> for the case when CTL are long-lived, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e168" xlink:type="simple"/></inline-formula>. Using simulation of the model (<xref ref-type="fig" rid="pcbi-1003878-g001">Figure 1A</xref>, <xref ref-type="disp-formula" rid="pcbi.1003878.e114">Equations 6</xref> to <xref ref-type="disp-formula" rid="pcbi.1003878.e116">8</xref>) with two sites per epitope, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e169" xlink:type="simple"/></inline-formula>, the pattern of escape is calculated for a range of recognition and fitness losses. The pattern that is obtained is plotted as a function of the parameters of recognition loss at the first and second site (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e170" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e171" xlink:type="simple"/></inline-formula>, respectively). In each panel, certain parameters are fixed in order to focus on the effect of recognition loss. Fixed parameters are: the escape rate of the first haplotype and the number of targeted epitopes: <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e172" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e173" xlink:type="simple"/></inline-formula> (A,C) which correspond to early infection and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e174" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e175" xlink:type="simple"/></inline-formula> (B,D) which correspond to chronic infection. Fitness costs are chosen such that the second site is less costly than the first: <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e176" xlink:type="simple"/></inline-formula> equal to 3 (A,B) or much less costly than the first, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e177" xlink:type="simple"/></inline-formula> (C,D). Other parameters given in <xref ref-type="table" rid="pcbi-1003878-t001">Table 1</xref>. Equations S6 (red line) and S9 (blue line) determine the region where the leapfrog pattern can be observed. Regions that require <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e178" xlink:type="simple"/></inline-formula> are not allowed by definition (magenta line). The shaded regions between these three lines correspond to regions of parameter space where both sites escape. The corresponding patterns are: “leapfrog” (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e179" xlink:type="simple"/></inline-formula>, <xref ref-type="fig" rid="pcbi-1003878-g004">Figure 4C</xref>), “nested” (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e180" xlink:type="simple"/></inline-formula>, <xref ref-type="fig" rid="pcbi-1003878-g004">Figure 4E</xref>), “nested leapfrog” (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e181" xlink:type="simple"/></inline-formula>). Observation of the leapfrog pattern in an epitope tightly constrains the fraction of CTL recognition loss conferred by sites in an epitope. The inset shows the length of time during which haplotype 01 is dominant in the escaping epitope. When CTLs are long-lived, the leapfrog pattern (<xref ref-type="fig" rid="pcbi-1003878-g004">Figure 4C</xref>) is observed more often, since the haplotype 01 has time to grow to dominate the population. The death rate of CTL is <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e182" xlink:type="simple"/></inline-formula>, ten times smaller than the value used in <xref ref-type="fig" rid="pcbi-1003878-g005">Figure 5</xref>. The difference between the predicted leapfrog region as determined by Equations S6 (red line) and S9 (blue line) and the shaded region where leapfrog is actually observed is lessened for long-lived CTL. This is the case because each time that haplotype 01 gains the advantage over haplotype 10, it grows to dominate the population before CTL decay to the level where haplotype 01 also reverts.</p>
<p>(TIF)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003878.s004" mimetype="application/pdf" xlink:href="info:doi/10.1371/journal.pcbi.1003878.s004" position="float" xlink:type="simple"><label>Text S1</label><caption>
<p><bold>Steady state and the escape rate.</bold></p>
<p>(PDF)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003878.s005" mimetype="application/pdf" xlink:href="info:doi/10.1371/journal.pcbi.1003878.s005" position="float" xlink:type="simple"><label>Text S2</label><caption>
<p><bold>Escape causes contraction of CTL clones.</bold></p>
<p>(PDF)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003878.s006" mimetype="application/pdf" xlink:href="info:doi/10.1371/journal.pcbi.1003878.s006" position="float" xlink:type="simple"><label>Text S3</label><caption>
<p><bold>General conditions for observing the leapfrog pattern of escape.</bold></p>
<p>(PDF)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003878.s007" mimetype="application/pdf" xlink:href="info:doi/10.1371/journal.pcbi.1003878.s007" position="float" xlink:type="simple"><label>Text S4</label><caption>
<p><bold>Simulation: Leapfrog pattern can occur in a broad range of fitness and recognition losses.</bold></p>
<p>(PDF)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003878.s008" mimetype="application/pdf" xlink:href="info:doi/10.1371/journal.pcbi.1003878.s008" position="float" xlink:type="simple"><label>Text S5</label><caption>
<p><bold>Finding the relationship between </bold><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003878.e183" xlink:type="simple"/></inline-formula><bold> and HLA binding loss from three different experiments.</bold></p>
<p>(PDF)</p>
</caption></supplementary-material></sec></body>
<back>
<ack>
<p>We thank Todd Allen, Christian Boutwell, John Coffin, Richard Neher, Damien Tully, Alan Perelson, and Leor Weinberger for helpful comments and discussion.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pcbi.1003878-Schmitz1"><label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schmitz</surname><given-names>JE</given-names></name> (<year>1999</year>) <article-title>Control of Viremia in Simian Immunodeficiency Virus Infection by CD8+ Lymphocytes</article-title>. <source>Science</source> <volume>283</volume>: <fpage>857</fpage>–<lpage>860</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Jin1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jin</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Bauer</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Tuttleton</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lewin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gettie</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus–infected macaques</article-title>. <source>The Journal of experimental medicine</source> <volume>189</volume>: <fpage>991</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Finlay1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Finlay</surname><given-names>BB</given-names></name>, <name name-style="western"><surname>McFadden</surname><given-names>G</given-names></name> (<year>2006</year>) <article-title>Anti-Immunology: Evasion of the Host Immune System by Bacterial and Viral Pathogens</article-title>. <source>Cell</source> <volume>124</volume>: <fpage>767</fpage>–<lpage>782</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Rouzine1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rouzine</surname><given-names>IM</given-names></name>, <name name-style="western"><surname>Coffin</surname><given-names>JM</given-names></name> (<year>1999</year>) <article-title>Linkage disequilibrium test implies a large effective population number for HIV in vivo</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <volume>96</volume>: <fpage>10758</fpage>–<lpage>10763</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Turnbull1"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Turnbull</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>NA</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Kinetics of Expansion of Epitope-Specific T Cell Responses during Primary HIV-1 Infection</article-title>. <source>The Journal of Immunology</source> <volume>182</volume>: <fpage>7131</fpage>–<lpage>7145</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Karlsson1"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Karlsson</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Iversen</surname><given-names>AKN</given-names></name>, <name name-style="western"><surname>Chapman</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>de Oliviera</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Spotts</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape</article-title>. <source>PLoS ONE</source> <volume>2</volume>: <fpage>e225</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Liu1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname><given-names>MKP</given-names></name>, <name name-style="western"><surname>Hawkins</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Ritchie</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Ganusov</surname><given-names>VV</given-names></name>, <name name-style="western"><surname>Whale</surname><given-names>V</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Vertical T cell immunodominance and epitope entropy determine HIV-1 escape</article-title>. <source>J Clin Invest</source> <volume>123</volume>: <fpage>380</fpage>–<lpage>93</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Leslie1"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Leslie</surname><given-names>A</given-names></name> (<year>2005</year>) <article-title>Transmission and accumulation of ctl escape variants drive negative associations between hiv polymorphisms and hla</article-title>. <source>Journal of Experimental Medicine</source> <volume>201</volume>: <fpage>891</fpage>–<lpage>902</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Friedrich1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Friedrich</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Dodds</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Yant</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Vojnov</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Rudersdorf</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Reversion of ctl escape–variant immunodeficiency viruses in vivo</article-title>. <source>Nat Med</source> <volume>10</volume>: <fpage>275</fpage>–<lpage>281</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Troyer1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Troyer</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>McNevin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Krizan</surname><given-names>RW</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Variable Fitness Impact of HIV-1 Escape Mutations to Cytotoxic T Lymphocyte (CTL) Response</article-title>. <source>PLoS Pathogens</source> <volume>5</volume>: <fpage>e1000365</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Liu2"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Mcnevin</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Holte</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mcelrath</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Mullins</surname><given-names>JI</given-names></name> (<year>2011</year>) <article-title>Dynamics of viral evolution and ctl responses in hiv-1 infection</article-title>. <source>PLoS ONE</source> <volume>6</volume>: <fpage>e15639</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Ganusov1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ganusov</surname><given-names>VV</given-names></name>, <name name-style="western"><surname>Goonetilleke</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>MKP</given-names></name>, <name name-style="western"><surname>Ferrari</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Shaw</surname><given-names>GM</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Fitness Costs and Diversity of the Cytotoxic T Lymphocyte (CTL) Response Determine the Rate of CTL Escape during Acute and Chronic Phases of HIV Infection</article-title>. <source>Journal of Virology</source> <volume>85</volume>: <fpage>10518</fpage>–<lpage>10528</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Henn1"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Henn</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Boutwell</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Charlebois</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lennon</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Power</surname><given-names>KA</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Whole Genome Deep Sequencing of HIV-1 Reveals the Impact of Early Minor Variants Upon Immune Recognition During Acute Infection</article-title>. <source>PLoS Pathogens</source> <volume>8</volume>: <fpage>e1002529</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Althaus1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Althaus</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Boer</surname><given-names>RJD</given-names></name> (<year>2008</year>) <article-title>Dynamics of immune escape during hiv/siv infection</article-title>. <source>PLoS Computational Biology</source> <volume>4</volume>: <fpage>e1000103</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Mostowy1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mostowy</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kouyos</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Fouchet</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bonhoeffer</surname><given-names>S</given-names></name> (<year>2011</year>) <article-title>The Role of Recombination for the Coevolutionary Dynamics of HIV and the Immune Response</article-title>. <source>PLoS ONE</source> <volume>6</volume>: <fpage>e16052</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-vanDeutekom1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Deutekom</surname><given-names>HWM</given-names></name>, <name name-style="western"><surname>Wijnker</surname><given-names>G</given-names></name>, <name name-style="western"><surname>De Boer</surname><given-names>RJ</given-names></name> (<year>2013</year>) <article-title>The Rate of Immune Escape Vanishes When Multiple Immune Responses Control a HIV Infection</article-title>. <source>J Immunol</source> <volume>191</volume>: <fpage>3277</fpage>–<lpage>86</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Kearney1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kearney</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Maldarelli</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Shao</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Margolick</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Daar</surname><given-names>ES</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Human Immunodeficiency Virus Type 1 Population Genetics and Adaptation in Newly Infected Individuals</article-title>. <source>Journal of Virology</source> <volume>83</volume>: <fpage>2715</fpage>–<lpage>2727</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Fryer1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fryer</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Frater</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Duda</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Roberts</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Phillips</surname><given-names>RE</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Modelling the evolution and spread of HIV immune escape mutants</article-title>. <source>PLoS Pathogens</source> <volume>6</volume>: <fpage>e1001196</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Kelleher1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kelleher</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Long</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Allen</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses</article-title>. <source>The Journal of experimental medicine</source> <volume>193</volume>: <fpage>375</fpage>–<lpage>386</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Crawford1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Crawford</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Matthews</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Schaefer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Carlson</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Leslie</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>The Hypervariable HIV-1 Capsid Protein Residues Comprise HLA-Driven CD8+ T-Cell Escape Mutations and Covarying HLA-Independent Polymorphisms</article-title>. <source>Journal of Virology</source> <volume>85</volume>: <fpage>1384</fpage>–<lpage>1390</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Song1"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Song</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Pavlicek</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Bhattacharya</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome</article-title>. <source>Retrovirology</source> <volume>9</volume>: <fpage>1</fpage>–<lpage>14</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Boutwell1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boutwell</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Carlson</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>Seese</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Power</surname><given-names>KA</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Frequent and variable cytotoxic-T-lymphocyte escape-associated fitness costs in the human immunodeficiency virus type 1 subtype B Gag proteins</article-title>. <source>Journal of Virology</source> <volume>87</volume>: <fpage>3952</fpage>–<lpage>3965</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Liu3"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Mcnevin</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Holte</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mcelrath</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Mullins</surname><given-names>JI</given-names></name> (<year>2011</year>) <article-title>Dynamics of Viral Evolution and CTL Responses in HIV-1 Infection</article-title>. <source>PLoS ONE</source> <volume>6</volume>: <fpage>e15639</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Cale1"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cale</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Hraber</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Giorgi</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Fischer</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Bhattacharya</surname><given-names>T</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Epitope-specific cd8+ t lymphocytes cross-recognize mutant simian immunodeficiency virus (siv) sequences but fail to contain very early evolution and eventual fixation of epitope escape mutations during siv infection</article-title>. <source>Journal of Virology</source> <volume>85</volume>: <fpage>3746</fpage>–<lpage>3757</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Ganusov2"><label>25</label>
<mixed-citation publication-type="other" xlink:type="simple">Ganusov VV, De Boer RJ (2005) Estimating Costs and Benefits of CTL Escape Mutations in SIV/HIV Infection. PLoS Computational Biology preprint: e24.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Mostowy2"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mostowy</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kouyos</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Hoof</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Hinkley</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Haddad</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Estimating the fitness cost of escape from HLA presentation in HIV-1 protease and reverse transcriptase</article-title>. <source>PLoS Computational Biology</source> <volume>8</volume>: <fpage>e1002525</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Schneidewind1"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schneidewind</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Brockman</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Sidney</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>YE</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid</article-title>. <source>Journal of Virology</source> <volume>82</volume>: <fpage>5594</fpage>–<lpage>5605</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Kawashima1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kawashima</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Pfafferott</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Frater</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Matthews</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Payne</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Adaptation of HIV-1 to human leukocyte antigen class I</article-title>. <source>Nature</source> <volume>458</volume>: <fpage>641</fpage>–<lpage>645</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Matthews1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Matthews</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Koyanagi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kloverpris</surname><given-names>HN</given-names></name>, <name name-style="western"><surname>Harndahl</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Stryhn</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Differential Clade-Specific HLA-B*3501 Association with HIV-1 Disease Outcome Is Linked to Immunogenicity of a Single Gag Epitope</article-title>. <source>Journal of Virology</source> <volume>86</volume>: <fpage>12643</fpage>–<lpage>12654</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Goonetilleke1"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Goonetilleke</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Salazar-Gonzalez</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Ferrari</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Giorgi</surname><given-names>E</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>The first t cell response to transmitted/founder virus contributes to the control of acute viremia in hiv-1 infection</article-title>. <source>Journal of Experimental Medicine</source> <volume>206</volume>: <fpage>1253</fpage>–<lpage>1272</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Fischer1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fischer</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Ganusov</surname><given-names>VV</given-names></name>, <name name-style="western"><surname>Giorgi</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Hraber</surname><given-names>PT</given-names></name>, <name name-style="western"><surname>Keele</surname><given-names>BF</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing</article-title>. <source>PLoS ONE</source> <volume>5</volume>: <fpage>e12303</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Rouzine2"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rouzine</surname><given-names>IM</given-names></name>, <name name-style="western"><surname>Weinberger</surname><given-names>LS</given-names></name> (<year>2013</year>) <article-title>The quantitative theory of within-host viral evolution</article-title>. <source>Journal of Statistical Mechanics: Theory and Experiment</source> <volume>2013</volume>: <fpage>P01009</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Turnbull2"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Turnbull</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>NA</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Kinetics of expansion of epitope-specific t cell responses during primary hiv-1 infection</article-title>. <source>The Journal of Immunology</source> <volume>182</volume>: <fpage>7131</fpage>–<lpage>7145</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Kouyos1"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kouyos</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Althaus</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Bonhoeffer</surname><given-names>S</given-names></name> (<year>2006</year>) <article-title>Stochastic or deterministic: what is the effective population size of HIV-1?</article-title> <source>Trends in microbiology</source> <volume>14</volume>: <fpage>507</fpage>–<lpage>511</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Pennings1"><label>35</label>
<mixed-citation publication-type="other" xlink:type="simple">Pennings P, Kryazhimskiy S, Wakeley J (2014) PLOS Genetics: Loss and Recovery of Genetic Diversity in Adapting Populations of HIV. PLoS Genetics.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Richman1"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Richman</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Havlir</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Corbeil</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Looney</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ignacio</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>1994</year>) <article-title>Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy</article-title>. <source>Journal of Virology</source> <volume>68</volume>: <fpage>1660</fpage>–<lpage>1666</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Liu4"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Mullins</surname><given-names>JI</given-names></name>, <name name-style="western"><surname>Mittler</surname><given-names>JE</given-names></name> (<year>2006</year>) <article-title>Waiting times for the appearance of cytotoxic T-lymphocyte escape mutants in chronic HIV-1 infection</article-title>. <source>Virology</source> <volume>347</volume>: <fpage>140</fpage>–<lpage>146</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-QuionesMateu1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Quiñones-Mateu</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Arts</surname><given-names>EJ</given-names></name> (<year>2002</year>) <article-title>Fitness of drug resistant HIV-1: methodology and clinical implications</article-title>. <source>Drug Resistance Updates</source> <volume>5</volume>: <fpage>224</fpage>–<lpage>233</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Bonhoeffer1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bonhoeffer</surname><given-names>S</given-names></name> (<year>2004</year>) <article-title>Evidence for Positive Epistasis in HIV-1</article-title>. <source>Science</source> <volume>306</volume>: <fpage>1547</fpage>–<lpage>1550</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Hinkley1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hinkley</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Martins</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chappey</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Haddad</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Stawiski</surname><given-names>E</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase</article-title>. <source>Nature Genetics</source> <volume>43</volume>: <fpage>487</fpage>–<lpage>489</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Poon1"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Poon</surname><given-names>AFY</given-names></name>, <name name-style="western"><surname>Swenson</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>WWY</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Kosakovsky Pond</surname><given-names>SL</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Phylogenetic Analysis of Population-Based and Deep Sequencing Data to Identify Coevolving Sites in the nef Gene of HIV-1</article-title>. <source>Molecular Biology and Evolution</source> <volume>27</volume>: <fpage>819</fpage>–<lpage>832</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Rouzine3"><label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rouzine</surname><given-names>IM</given-names></name>, <name name-style="western"><surname>Coffin</surname><given-names>JM</given-names></name> (<year>1999</year>) <article-title>Search for the mechanism of genetic variation in the pro gene of human immunodeficiency virus</article-title>. <source>Journal of Virology</source> <volume>73</volume>: <fpage>8167</fpage>–<lpage>8178</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Kadolsky1"><label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kadolsky</surname><given-names>UD</given-names></name>, <name name-style="western"><surname>Asquith</surname><given-names>B</given-names></name> (<year>2010</year>) <article-title>Quantifying the Impact of Human Immunodeficiency Virus-1 Escape From Cytotoxic T-Lymphocytes</article-title>. <source>PLoS Computational Biology</source> <volume>6</volume>: <fpage>e1000981</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Haase1"><label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Haase</surname><given-names>AT</given-names></name> (<year>2011</year>) <article-title>Early Events in Sexual Transmission of HIV and SIV and Opportunities for Interventions</article-title>. <source>Annual review of medicine</source> <volume>62</volume>: <fpage>127</fpage>–<lpage>139</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Ogg1"><label>45</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ogg</surname><given-names>GS</given-names></name> (<year>1998</year>) <article-title>Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA</article-title>. <source>Science</source> <volume>279</volume>: <fpage>2103</fpage>–<lpage>2106</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Kuroda1"><label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kuroda</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Schmitz</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Charini</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Nickerson</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lifton</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys</article-title>. <source>Journal of immunology (Baltimore, Md: 1950)</source> <volume>162</volume>: <fpage>5127</fpage>–<lpage>5133</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Sergeev1"><label>47</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sergeev</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Batorsky</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Rouzine</surname><given-names>IM</given-names></name> (<year>2010</year>) <article-title>Model with two types of CTL regulation and experiments on CTL dynamics</article-title>. <source>Journal of Theoretical Biology</source> <volume>263</volume>: <fpage>369</fpage>–<lpage>384</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Batorsky1"><label>48</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Batorsky</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kearney</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Palmer</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Maldarelli</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Rouzine</surname><given-names>IM</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Estimate of effective recombination rate and average selection coefficient for HIV in chronic infection</article-title>. <source>Proceedings of the National Academy of Sciences</source> <volume>108</volume>: <fpage>5661</fpage>–<lpage>5666</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Neher1"><label>49</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Neher</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Shraiman</surname><given-names>BI</given-names></name>, <name name-style="western"><surname>Fisher</surname><given-names>DS</given-names></name> (<year>2010</year>) <article-title>Rate of Adaptation in Large Sexual Populations</article-title>. <source>Genetics</source> <volume>184</volume>: <fpage>467</fpage>–<lpage>481</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Elemans1"><label>50</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Elemans</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Florins</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Willems</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Asquith</surname><given-names>B</given-names></name> (<year>2014</year>) <article-title>Rates of CTL Killing in Persistent Viral Infection In Vivo</article-title>. <source>PLoS Computational Biology</source> <volume>10</volume>: <fpage>e1003534</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-SeichAlBasatena1"><label>51</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Seich Al Basatena</surname><given-names>NK</given-names></name>, <name name-style="western"><surname>Chatzimichalis</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Graw</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Frost</surname><given-names>SDW</given-names></name>, <name name-style="western"><surname>Regoes</surname><given-names>RR</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Can non-lytic CD8+ T cells drive HIV-1 escape?</article-title> <source>PLoS Pathogens</source> <volume>9</volume>: <fpage>e1003656</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Ho1"><label>52</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ho</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Neumann</surname><given-names>AU</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Leonard</surname><given-names>JM</given-names></name>, <etal>et al</etal>. (<year>1995</year>) <article-title>Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection</article-title>. <source>Nature</source> <volume>373</volume>: <fpage>123</fpage>–<lpage>126</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Perelson1"><label>53</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Perelson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Neumann</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Markowitz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Leonard</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>D</given-names></name> (<year>1996</year>) <article-title>Hiv-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time</article-title>. <source>Science</source> <volume>271</volume>: <fpage>1582</fpage>–<lpage>1586</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Markowitz1"><label>54</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Markowitz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Louie</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hurley</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Di Mascio</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo</article-title>. <source>Journal of Virology</source> <volume>77</volume>: <fpage>5037</fpage>–<lpage>5038</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Klatt1"><label>55</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Klatt</surname><given-names>NR</given-names></name>, <name name-style="western"><surname>Shudo</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ortiz</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Engram</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Paiardini</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells</article-title>. <source>PLoS Pathogens</source> <volume>6</volume>: <fpage>e1000747</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Wong1"><label>56</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wong</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Strain</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Porrata</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Reay</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Sankaran-Walters</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>In Vivo CD8+ T-Cell Suppression of SIV Viremia Is Not Mediated by CTL Clearance of Productively Infected Cells</article-title>. <source>PLoS Pathogens</source> <volume>6</volume>: <fpage>e1000748</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Klenerman1"><label>57</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Klenerman</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Phillips</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Rinaldo</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Wahl</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Ogg</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>1996</year>) <article-title>Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <volume>93</volume>: <fpage>15323</fpage>–<lpage>15328</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Rouzine4"><label>58</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rouzine</surname><given-names>IM</given-names></name>, <name name-style="western"><surname>Sergeev</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Glushtsov</surname><given-names>AI</given-names></name> (<year>2006</year>) <article-title>Two types of cytotoxic lymphocyte regulation explain kinetics of immune response to human immunodeficiency virus</article-title>. <source>Proceedings of the National Academy of Sciences</source> <volume>103</volume>: <fpage>666</fpage>–<lpage>671</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Sedaghat1"><label>59</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sedaghat</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Dinoso</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wilke</surname><given-names>CO</given-names></name>, <name name-style="western"><surname>Siliciano</surname><given-names>RF</given-names></name> (<year>2008</year>) <article-title>Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle</article-title>. <source>Proceedings of the National Academy of Sciences</source> <volume>105</volume>: <fpage>4832</fpage>–<lpage>4837</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Althaus2"><label>60</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Althaus</surname><given-names>C</given-names></name> (<year>2011</year>) <article-title>Implications of CTL-Mediated Killing of HIV-Infected Cells during the Non-Productive Stage of Infection</article-title>. <source>PLoS ONE</source> <volume>6</volume>: <fpage>e16468</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Elemans2"><label>61</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Elemans</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Basatena</surname><given-names>NKSA</given-names></name>, <name name-style="western"><surname>Klatt</surname><given-names>NR</given-names></name>, <name name-style="western"><surname>Gkekas</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Silvestri</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Why Don't CD8+ T Cells Reduce the Lifespan of SIV-Infected Cells In Vivo?</article-title> <source>PLoS Computational Biology</source> <volume>7</volume>: <fpage>e1002200</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Brodie1"><label>62</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brodie</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Lewinsohn</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Patterson</surname><given-names>BK</given-names></name>, <name name-style="western"><surname>Jiyamapa</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Krieger</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>In vivo migration and function of transferred HIV-1-specific cytotoxic T cells</article-title>. <source>Nature Medicine</source> <volume>5</volume>: <fpage>34</fpage>–<lpage>41</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Wick1"><label>63</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wick</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>OO</given-names></name>, <name name-style="western"><surname>Corey</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Self</surname><given-names>SG</given-names></name> (<year>2005</year>) <article-title>How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill?</article-title> <source>Journal of Virology</source> <volume>79</volume>: <fpage>13579</fpage>–<lpage>13586</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Asquith1"><label>64</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Asquith</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>CTT</given-names></name>, <name name-style="western"><surname>Lipsitch</surname><given-names>M</given-names></name>, <name name-style="western"><surname>McLean</surname><given-names>AR</given-names></name> (<year>2006</year>) <article-title>Inefficient Cytotoxic T Lymphocyte–Mediated Killing of HIV-1–Infected Cells In Vivo</article-title>. <source>PLoS Biology</source> <volume>4</volume>: <fpage>e90</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Sergeev2"><label>65</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sergeev</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Batorsky</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Coffin</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Rouzine</surname><given-names>IM</given-names></name> (<year>2010</year>) <article-title>Interpreting the effect of vaccination on steady state infection in animals challenged with Simian immunodeficiency virus</article-title>. <source>Journal of Theoretical Biology</source> <volume>263</volume>: <fpage>385</fpage>–<lpage>392</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Ganusov3"><label>66</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ganusov</surname><given-names>VV</given-names></name>, <name name-style="western"><surname>De Boer</surname><given-names>RJ</given-names></name> (<year>2008</year>) <article-title>Estimating In Vivo Death Rates of Targets due to CD8 T-Cell-Mediated Killing</article-title>. <source>Journal of Virology</source> <volume>82</volume>: <fpage>11749</fpage>–<lpage>11757</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Pan1"><label>67</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Baldauf</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Keppler</surname><given-names>OT</given-names></name>, <name name-style="western"><surname>Fackler</surname><given-names>OT</given-names></name> (<year>2013</year>) <article-title>Restrictions to HIV-1 replication in resting CD4+ T lymphocytes</article-title>. <source>Cell research</source> <volume>23</volume>: <fpage>876</fpage>–<lpage>885</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Li1"><label>68</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Estes</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>ZM</given-names></name>, <name name-style="western"><surname>Rourke</surname><given-names>T</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells</article-title>. <source>Nature</source> <volume>434</volume>: <fpage>1148</fpage>–<lpage>1152</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Kuroda2"><label>69</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kuroda</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Schmitz</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Charini</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Nickerson</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lifton</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys</article-title>. <source>Journal of immunology (Baltimore, Md: 1950)</source> <volume>162</volume>: <fpage>5127</fpage>–<lpage>5133</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003878-Ogg2"><label>70</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ogg</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Bonhoeffer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Moss</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Nowak</surname><given-names>MA</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy</article-title>. <source>Journal of Virology</source> <volume>73</volume>: <fpage>797</fpage>–<lpage>800</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>